Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
2 Bulletproof Dividend Stocks to Buy in July
09:40am, Friday, 04'th Jul 2025
While a high dividend yield is attractive, the consistency makes a stock worth holding.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
01:11pm, Thursday, 03'rd Jul 2025
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Could Be a Great Choice
12:46pm, Thursday, 03'rd Jul 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
10:00am, Thursday, 03'rd Jul 2025
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations
08:41am, Thursday, 03'rd Jul 2025
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care,
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
10:10am, Wednesday, 02'nd Jul 2025
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
06:45pm, Tuesday, 01'st Jul 2025
Johnson & Johnson (JNJ) concluded the recent trading session at $155.92, signifying a +2.08% move from its prior day's close.
I Have Invested in Dividends for 25 Years—These Are the Best Picks to Turn You Into a Believer
08:32am, Tuesday, 01'st Jul 2025
Among patient investors, dividend investing has remained a standard financial strategy.
AI builds ideal dividend stock portfolio for H2 2025
07:16am, Tuesday, 01'st Jul 2025
In the first six months of 2025, the stock market has been on a roller-coaster ride, hitting both lows and highs driven by trade tariff uncertainties and geopolitical tensions.
Johnson & Johnson: Patience Will Be Rewarded
11:13am, Monday, 30'th Jun 2025
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, t
This Changes Everything: One Of The Most Important Shifts For Dividend Investors
07:30am, Monday, 30'th Jun 2025
Inflation isn't just back, it's becoming policy. From skewed CPI data to deficit-driven dollar moves, we're entering a new and lasting macro era. The U.S. may now prefer higher inflation to fix its ba
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
04:12am, Friday, 27'th Jun 2025
Johnson & Johnson (JNJ -0.18%) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices.
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
10:41am, Thursday, 26'th Jun 2025
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever
08:45am, Thursday, 26'th Jun 2025
The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's p
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
11:49am, Tuesday, 24'th Jun 2025
Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat cor
